MOTS-c (MOTS-C)

One MOTS-c pen — ₴4,250, 20-day course (4 injections). For extended 40-day course, 2 pens needed. Detailed selection — free DOZA consultation.

MOTS-c is studied as a metabolic peptide: it activates AMPK — the cell's "energy sensor". In preclinical studies (HFD mice, Lee et al., Cell Metabolism 2015) this prevented obesity and improved insulin sensitivity. To be honest: the clinical weight-loss efficacy of MOTS-c in humans has not been established — there are no controlled trials administering the peptide to humans for weight loss. DOZA clients most often report a subjective increase in energy and endurance (self-reported impressions). If your goal is weight loss specifically, discuss products with proven clinical efficacy with a DOZA specialist.

There is no dedicated clinical weight-loss statistic for MOTS-c yet — its weight-loss efficacy in humans has not been established, and most data come from preclinical studies. DOZA clients most often report a subjective increase in energy and endurance during the course; these are individual self-reported impressions, not clinical trial results. We publish real client reviews on the MOTS-c results page as they are collected.

Standard MOTS-c dosage according to Pen Peptide manufacturer protocol: **2.5 mg (50 pen units) subcutaneously once every 4–5 days**. One pen (10 mg = 200 units × 50 mcg) contains 4 doses for 20-day course. Precise course selection — free DOZA consultation.

MOTS-c and Mounjaro have different mechanisms of action: tirzepatide works through GIP/GLP-1 receptors, while MOTS-c is studied in relation to AMPK and mitochondrial metabolism. There are currently no controlled clinical trials proving additional weight loss from the MOTS-c + Mounjaro combination in humans. No pharmacological conflict between them has been described. If you are on a Mounjaro course and interested in MOTS-c — discuss it with a DOZA specialist, who will check compatibility with your protocol.

MOTS-c from Pen Peptide has ≥98% purity, produced in certified European GMP laboratories. MSSPT molecular stabilization technology (Molecular Structure Stabilization Process Technology) is applied — buffers, antioxidants and stabilizing agents preserve peptide bioactivity even during brief temperature increases during transportation. Pen contains pre-dissolved solution, no mixing required.

There are no direct clinical trials where MOTS-c was administered to humans to assess sleep or cognitive function. A Nature Communications 2021 study showed that endogenous MOTS-c levels rise in humans after exercise (n=10), and peptide administration improved physical performance in mice — including aged animals. The hypothesis about sleep and mental clarity is based on the peptide's mitochondrial role (more ATP — more efficient overnight recovery), but there is no clinical confirmation yet. Some DOZA clients subjectively report deeper sleep during the course — these are self-reported impressions.

According to Pen Peptide manufacturer recommendations, MOTS-c combines well with: Ipamorelin (GH stimulation, anti-aging), CJC-1295 NO DAC (enhanced GH release), PEG-MGF (muscle regeneration). In DOZA protocol, combination with NAD+ is also actively used — dual mitochondrial energy support. Combination selection is individual — free DOZA consultation 24/7.

MOTS-c has many spellings depending on language and user preference. Latin: MOTS-c, MOTS-C, mots c, motc, motc-s, mots peptide. Cyrillic: Мотс-С, мотс пептид, мотс с, мотс-с, мотц, моц препарат, мотц препарат. Scientific full name — Mitochondrial Open Reading Frame of the 12S rRNA-c (mitochondrial open reading frame peptide). Scientific publications also use "mitochondrial peptide" — general category including MOTS-c.

MOTS-c is a mitochondrial peptide studied in several directions. Main use-cases with an honest evidence status: • Metabolism: activates the AMPK pathway (the cell's "energy sensor") — mechanism confirmed in preclinical studies (Lee et al., Cell Metabolism 2015, PubMed 25738459) • Insulin sensitivity: in HFD mice, MOTS-c improved insulin sensitivity (~30% higher glucose infusion rate in clamp testing, Cell Metabolism 2015). Not a diabetes treatment — specialized therapy is prescribed by a physician • Energy and endurance: endogenous MOTS-c levels rise in humans after exercise (Nature Communications 2021, n=10); peptide administration improved endurance in mice, including aged animals • Cognitive function and sleep: preliminary data from animal models; no clinical studies in humans • Anti-aging and muscle support: in preclinical work MOTS-c reduced oxidative stress markers and supported muscle function MOTS-c is not an obesity treatment drug and is sold as a research peptide. DOZA clients choose it as a standalone metabolic peptide — for energy and metabolism support; a free specialist consultation is available before starting.

Pen Peptide brand produces MOTS-c only in pen format 10 mg for subcutaneous injections — no nasal sprays in their catalog. DOZA supplies exactly this format: pen with 200 units of 50 mcg each, precise dosing and 2–8°C cold chain throughout from manufacturer to client. If offered MOTS-c as nasal spray — this is another manufacturer's product or different release form that DOZA doesn't work with. We don't have access to testing such products and cannot comment on their purity, dosing or effectiveness.

Pen Peptide brand produces MOTS-c in one dosage — 10 mg pen (200 units × 50 mcg). This is complete 20-day course: 4 injections of 2.5 mg (50 pen units) once every 4–5 days. For extended 40-day course — 2 pens. If offered MOTS-c in 20, 30, 40 mg dosages (usually powder vial format) — these are other manufacturers' products that DOZA doesn't work with. We don't have access to testing these products and cannot comment on their purity, dosing or composition. Before purchasing from any supplier — ask for certificate of analysis (CoA) for specific batch. What we can guarantee regarding Pen Peptide 10 mg format: • Precise dosing — 50 mcg per unit, no powder reconstitution • Ready 20-day manufacturer protocol • Stabilized formula (MSSPT) — according to manufacturer claims • 2–8°C cold chain throughout delivery path • Manufacturer quality certificate on client request

A lyophilized vial is a powder that must be reconstituted with bacteriostatic water before use, with the dose drawn manually using an insulin syringe. The Pen Peptide pre-filled pen is a ready stabilized solution: no reconstitution, the dose is measured by dial clicks (50 units = 2.5 mg), a closed sterile system without repeated punctures. Vials are usually cheaper but require experience, extra consumables, and precision when reconstituting and storing the prepared solution. For home use without medical experience, the pen is the more practical and safer format.

The pen price includes a finished sterile form: factory reconstitution and solution stabilization (MSSPT technology), a precise dose dial (200 units × 50 mcg), a closed system without repeated cap punctures, and a 2–8°C cold chain. A powder vial is cheaper because reconstitution, syringes, and responsibility for dose accuracy fall on the user. At DOZA, the original Pen Peptide 10 mg pen costs 4,250 UAH — a full 20-day course with a free specialist consultation.

Pen Peptide manufacturer protocol: dose 2.5 mg (50 pen units) subcutaneously once every 4–5 days, 20-day course — 4 injections from one 10 mg pen. Inject into the abdomen or front of the thigh, preferably in the morning; wait 10 seconds before removing the needle, rotate injection sites. Store the pen refrigerated at 2–8°C, do not freeze. Full instructions with the pen unit table are in the "How to take" section on this page. Before starting the course — a free DOZA specialist consultation.

No, MOTS-c is not FDA-approved as a drug — it is sold as a research peptide. Current regulatory status: in April 2026 the FDA removed MOTS-c from Category 2 of the 503A list, and on July 23, 2026 it was reviewed by the PCAC advisory committee (proposed uses — obesity and osteoporosis). FDA scientific staff recommended AGAINST including MOTS-c in the 503A Bulks List due to insufficient efficacy and safety data in humans, yet the committee voted 7–5–2 IN FAVOR of including both forms (free base and acetate). This is an advisory vote: the final FDA decision is still pending, and it is not a drug approval. Human data remain limited: endogenous MOTS-c has been shown to rise after exercise (Nature Communications 2021, n=10); the efficacy of administering the peptide to humans for weight loss has not been clinically established. That is why DOZA accompanies every course with a free specialist consultation.